KeyBanc reiterates Sector Weight on Azenta stock after conference By Investing.com
KeyBanc has reiterated a Sector Weight rating on Azenta, Inc. (NASDAQ:AZTA) following the Society for Laboratory Automation and Screening 2026 Conference, noting positive signals for the life science sector despite the stock's 36.97% decline over the past year. The company recently showcased its BioArc Ultra automated storage system and reported mixed Q1 2026 earnings with a revenue beat but an EPS miss, prompting TD Cowen to lower its price target. Azenta is also advancing space research through a partnership with Frontier Space.
KeyBanc reiterates Sector Weight on Azenta stock after conference
KeyBanc has reiterated a Sector Weight rating on Azenta, Inc. following positive signals for the life science sector observed at a recent conference, despite the stock's 36.97% decline over the past year. The company showcased its BioArc Ultra automated storage system at a sold-out pre-conference event. Recent financial results showed an EPS miss but a revenue beat for Q1 2026, leading TD Cowen to lower its price target due to declining gross margins, while Azenta also partnered with Frontier Space for the EGGS-2 mission.
Azenta to Participate in the Stephens Annual Investment Conferen
Azenta, Inc. (Nasdaq: AZTA) announced its management will participate in the Stephens Annual Investment Conference in Nashville, Tennessee, on November 15-16, 2023. The company will host a presentation on November 16, 2023, at 11:00 am CT, with a live webcast available on its investor relations website. Azenta is a global provider of life sciences solutions, offering cold-chain sample management and multiomics services for drug development and clinical research.
Caprock Group LLC Invests $1.64 Million in Azenta, Inc. $AZTA
Caprock Group LLC has acquired a new stake of 53,707 shares in Azenta, Inc. (NASDAQ:AZTA) valued at approximately $1.64 million during the third quarter, representing 0.12% ownership. Azenta's board has also authorized a $250 million share buyback program, indicating management's view that the stock may be undervalued despite missing consensus on its latest EPS report. Analysts currently have an average "Hold" rating on Azenta with a price target of $41.33.
AlphaQuest LLC Decreases Stake in Azenta, Inc. $AZTA
AlphaQuest LLC significantly reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 91.8% in Q3, selling 47,738 shares and retaining 4,240 shares valued at $122,000. This comes as Azenta missed EPS expectations but exceeded revenue forecasts in its latest quarter, while analysts generally rate the stock as "Hold" with a consensus price target of $41.33. The company has also authorized a $250 million share buyback program.
Azenta’s Space Trials Put Sample Tools And Valuation In New Focus
Azenta, Inc. (NasdaqGS:AZTA) has partnered with Frontier Space to test its sample management technologies in microgravity for space-based life sciences research. This collaboration could validate Azenta's solutions for demanding environments and provide new reference points for biopharma, academic, and government customers. Investors are watching how this high-profile testing ground, along with the company's valuation metrics, will impact its future earnings and market position.
The Top 5 Analyst Questions From Azenta's Q4 Earnings Call
Azenta's Q4 earnings call revealed flat sales, with revenue slightly above estimates but non-GAAP profit and adjusted EBITDA missing expectations, leading to a negative market response. CEO John Marotta acknowledged ongoing operational challenges, including quality issues and macroeconomic headwinds, describing the quarter as transitional. Analysts focused on margin recovery, second-half acceleration, near-term revenue, U.S. academic markets, and the permanence of automated store quality remediations.
Azenta partners with Frontier Space to advance space research
Azenta, Inc. has announced a strategic partnership with Frontier Space to conduct scientific experiments in microgravity environments, including participation in the EGGS-2 mission. The collaboration utilizes Azenta’s specialized FluidX 0.26mL tubes for secure transport of experimental samples and focuses on evaluating thermal management capabilities for life sciences research in space. Despite this advancement, Azenta recently reported a miss on EPS forecasts but exceeded revenue expectations for Q1 2026, leading TD Cowen to revise its price target to $30 from $39 with a Hold rating.
How Azenta's lab tubes are being tested for life science in space
Azenta Life Sciences has partnered with Frontier Space to test its FluidX 0.26mL sample tubes in microgravity aboard the EGGS-2 mission, launched in January 2026. This collaboration aims to evaluate the tubes' durability and the SpaceLab Mk 2 platform's thermal management capabilities in space, extending Azenta's sample management technology into new research environments. The initiative is a strategic step for both companies to advance space-based life sciences research and biomanufacturing.
Azenta stock hits 52-week high at $28.44 despite yearly decline
Azenta Inc. stock recently reached a 52-week high of $28.44, yet it has experienced a 45.11% decline over the past year. Despite being in oversold territory and trading below its Fair Value with a strong balance sheet, the company reported a miss on EPS forecasts but exceeded revenue expectations in its first-quarter 2026 earnings. Analysts have adjusted price targets due to lower gross margins, highlighting the stock's volatility for investors.
Azenta (NASDAQ:AZTA) Downgraded to "Hold" Rating by Wall Street Zen
Wall Street Zen has downgraded Azenta (NASDAQ:AZTA) from a "buy" to a "hold" rating, aligning with MarketBeat's consensus "Hold" rating and an average target price of $41.33. This downgrade follows Azenta's recent quarterly earnings, where it reported $0.09 EPS, missing estimates by $0.02, though revenue slightly exceeded expectations. Despite the downgrade, Azenta's board authorized a $250 million stock buyback program, signaling management's belief that the stock may be undervalued.
Azenta, Inc. (NASDAQ:AZTA) Q1 2026 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA) announced its Q1 2026 earnings, reporting $0.09 EPS, missing expectations of $0.11. The company's organic revenue declined by approximately 1% year-over-year, largely due to cautious capital spending and government funding uncertainties. Despite this, Azenta reaffirmed its full-year 2026 guidance for 3% to 5% organic revenue growth and about 300 basis points of adjusted EBITDA margin expansion, anticipating a stronger second half as growth initiatives gain traction and quality issues in automated stores are resolved.
Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation
Azenta, Inc. (AZTA), formerly Brooks Automation, has undergone a significant transformation from a semiconductor automation company to a pure-play life sciences firm focused on cold chain sample management and multiomics. Despite a strong, debt-free balance sheet, the company faces scrutiny due to recent operational challenges and missed earnings targets after its Q1 2026 results. The article explores whether Azenta's critical role in biobanking infrastructure makes it a long-term value investment, contingent on its ability to execute its "Sample-to-Insight" strategy and improve profit margins.
Stocks making big moves yesterday: Azenta, FTAI Aviation, Reddit, Columbia Sportswear, and RenaissanceRe
This article details the stock movements of several companies yesterday. Azenta, FTAI Aviation, and Reddit experienced declines due to mixed earnings, profit-taking, and investor concerns over AI competition, respectively. Columbia Sportswear and RenaissanceRe saw their stocks rise after reporting better-than-expected fourth-quarter results and providing encouraging forecasts.
Azenta shares slide after Q1 earnings come in below forecasts
The article reports that Azenta Inc. (AZTA) shares fell after its first-quarter earnings and revenue missed analyst expectations. Despite the miss, the company reiterated its full-year guidance, which was largely in line with forecasts. Analysts from Goldman Sachs and Morgan Stanley adjusted their price targets for Azenta, with Goldman Sachs maintaining a "Buy" rating.
Azenta's (NASDAQ:AZTA) Q4 CY2025: Beats On Revenue
Azenta (NASDAQ:AZTA) reported Q4 CY2025 results, beating Wall Street's revenue expectations with sales of $148.6 million, though revenue was flat year-on-year. The company's non-GAAP profit per share was in line with analyst estimates. Despite revenue declines over the last five years, Azenta's Sample Management segment has shown growth, and analysts project a 5.4% revenue increase over the next 12 months.
Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
Azenta, Inc. reported its financial results for the first quarter of fiscal year 2026, ending December 31, 2025. The company announced revenues of $149 million, a 1% increase year-over-year, and a diluted EPS from continuing operations of ($0.11). Azenta also reiterated its full-year fiscal 2026 guidance, expecting total organic revenue growth of 3% to 5% and adjusted EBITDA margin expansion of approximately 300 basis points.
Azenta Stock Falls 22% Over Wider Loss EPS In Q1
Azenta, Inc. (AZTA) stock dropped approximately 22% in Wednesday morning trading following the announcement of its first-quarter financial results. The company reported a wider loss of $0.34 per share, compared to $0.25 per share in the previous year, despite an increase in revenue to $149 million from $147 million. The stock was trading at $28.78, down $8.01 from its previous close.
Earnings Flash (AZTA) Azenta, Inc. Reports Q1 Revenue $149.0M, vs. FactSet Est of $147.1M
Azenta, Inc. (AZTA) reported its Q1 revenue at $149.0 million, surpassing FactSet's estimate of $147.1 million. Despite the revenue increase, the company's fiscal Q1 non-GAAP earnings per share reportedly fell to $0.09, below the FactSet estimate of $0.14, leading to a drop in shares. Azenta also reiterated its earnings guidance for the full fiscal year 2026.
Azenta director Alan P. Malus resigns from board for new full-time role
Azenta, Inc. announced the resignation of Alan P. Malus from its Board of Directors and the Human Resources and Compensation Committee, effective Wednesday. His departure is due to him taking on a full-time role with another organization, which would prevent him from dedicating sufficient time to Azenta duties. The company clarified that his resignation was not due to any disagreements with Azenta's operations or policies.
Azenta (AZTA) To Report Earnings Tomorrow: Here Is What To Expect
Azenta (NASDAQ:AZTA) is set to report earnings this Wednesday. Analysts expect flat year-on-year revenue of $147 million and adjusted earnings of $0.13 per share. The company has missed revenue estimates five times in the last two years, and its stock is currently trading below the average analyst price target.
Azenta Shareholders Reaffirm Board, Pay Plans and Auditor
Azenta shareholders recently held their annual meeting where they re-elected all nominated directors, approved executive compensation packages, extended the 2020 Equity Incentive Plan with more shares, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year. Despite a "Hold" analyst rating and a "Neutral" AI analyst score due to mixed financial performance, these actions show continued support for management's strategies and governance. The company's financial overview indicates persistent losses alongside a strong balance sheet.
Azenta Shareholders Reaffirm Board, Pay Plans and Auditor
Azenta (AZTA) shareholders re-elected all nominated directors, approved executive compensation, authorized additional equity shares, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year at their annual meeting on January 28, 2026. This reflects continued support for the company's governance and strategic flexibility. TipRanks' AI Analyst, Spark, maintains a Neutral score for AZTA, citing mixed financial performance but supportive corporate actions.
Azenta schedules Feb. 4 webcast to review fiscal Q1 2026 results
Azenta (Nasdaq: AZTA) will release its fiscal first quarter 2026 earnings, which ended December 31, 2025, on Wednesday, February 4, 2026, before market open. The company will host a conference call and live webcast to discuss these results on the same day at 8:30 a.m. Eastern Time. Investors and media can access the webcast via the Azenta website, with a replay available from February 5, 2026.
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) is scheduled to announce its fiscal first quarter 2026 earnings, which ended December 31, 2025, on February 4, 2026, before market open. The company will also host a conference call and live webcast on the same day at 8:30 a.m. Eastern Time to discuss the financial results. Investors can access the webcast via the Azenta website, with a replay available starting February 5, 2026.
Azenta Announces Fiscal 2026 First Quarter Conference Call and Webcast
Azenta, Inc. (Nasdaq: AZTA) will release its fiscal first-quarter 2026 earnings on Wednesday, February 4, 2026, before market open. The company will also host a conference call and live webcast on the same day at 8:30 a.m. Eastern Time to discuss the financial results. Interested parties can access the webcast via the Azenta website, with a replay available from February 5, 2026.
Stephens Investment Management Group LLC Grows Stake in Azenta, Inc. $AZTA
Stephens Investment Management Group LLC increased its stake in Azenta, Inc. ($AZTA) by 19.7% in Q3, now owning 2.11% of the company's stock valued at $27.74 million. Azenta reported better-than-expected Q3 earnings and revenue, but has a negative net margin and P/E ratio, leading to mixed financials. The company's board approved a $250 million share repurchase plan, and analyst ratings are varied, with an average "Hold" rating and a $41.83 price target.
Azenta, Inc. $AZTA Shares Purchased by Nordea Investment Management AB
Nordea Investment Management AB significantly increased its stake in Azenta, Inc. (NASDAQ:AZTA) by 80% in Q3, acquiring 119,397 additional shares to bring its total holding to 268,597 shares, valued at approximately $7.54 million. This increased ownership, alongside other institutional investments, highlights investor interest in Azenta. The company recently surpassed earnings and revenue estimates and authorized a $250 million share buyback, indicating management's belief that the stock may be undervalued.
Conestoga Capital Advisors LLC Sells 450,370 Shares of Azenta, Inc. $AZTA
Conestoga Capital Advisors LLC reduced its stake in Azenta, Inc. by 23.5% in the third quarter, selling 450,370 shares but still owning 1,467,996 shares valued at $42.16 million. Despite this sale, Azenta's board authorized a $250 million share buyback, signaling confidence in the company's valuation. Analyst ratings are mixed, with a consensus "Hold" but some recent upgrades and increased price targets.
Azenta, Inc. (NASDAQ:AZTA) Given Average Recommendation of "Hold" by Analysts
Nine analysts have given Azenta, Inc. (NASDAQ:AZTA) an average "Hold" rating, with a 12-month average price target of $41.83. Institutional investors own approximately 99.08% of the stock, with several firms increasing their stakes. The company recently reported beating EPS estimates, 5.7% year-over-year revenue growth, and approved a $250 million share repurchase program.
Why Azenta (AZTA) Got an Analyst Upgrade After Mixed Results and What It Implies for Automation
Azenta received an "Outperform" upgrade from Evercore ISI Group despite mixed financial results, indicating increased analyst confidence in its future. The upgrade reinforces Azenta's investment narrative focused on biopharma sample management, automation, and sequencing, particularly highlighting its M&A pipeline for tuck-in deals. However, investors are cautioned to monitor potential risks from customer budget constraints and order delays affecting higher-margin products.
Azenta (AZTA) Analyst Rating Maintained, Price Target Raised to $39 by TD Cowen | AZTA Stock News
TD Cowen has maintained a 'Hold' rating for Azenta (AZTA) and increased its price target to $39, up from $35. This adjustment reflects a cautiously optimistic outlook for the company's NASDAQ performance. Other analysts have also recently upgraded Azenta's ratings and price targets, indicating a generally positive sentiment in the market.
Why Are Azenta (AZTA) Shares Soaring Today
Shares of Azenta (NASDAQ:AZTA) jumped 7.3% after Evercore ISI Group upgraded the company's rating to "Outperform" and raised its price target to $50.00 from $34.00, signaling strong analyst confidence. This significant upgrade follows a period of volatility for Azenta, which recently announced mixed Q3 financial results with a revenue miss despite a profit beat. Despite today's gains, Azenta is still trading below its 52-week high.
Azenta Enters Agreement for the Sale of its B Medical Systems Business to THELEMA S.À R.L.
Azenta, Inc. announced an agreement to sell its B Medical Systems business to THELEMA S.À R.L. for $63 million, with the transaction expected to close by March 31, 2026. This sale aims to simplify Azenta's portfolio, strengthen the company, and create long-term value for shareholders. B Medical Systems is a Luxembourg-based manufacturer and distributor of medical refrigeration devices.
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Azenta, Inc. $AZTA
Allspring Global Investments Holdings LLC reduced its stake in Azenta, Inc. by 4.2% in the last quarter, selling 57,100 shares. Despite this, Azenta's board has approved a $250 million share repurchase program, suggesting management views the stock as undervalued. The company recently reported earnings that beat consensus estimates, although it still maintains a negative net margin, and analysts have a "Hold" rating with an average price target of $39.00.
Azenta to sell B Medical Systems business for $63 million By Investing.com
Azenta, Inc. announced a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for $63 million, a move aimed at simplifying its portfolio and prioritizing core capabilities. The transaction, expected to close by March 31, 2026, will deploy proceeds to strengthen Azenta and drive long-term shareholder value. This follows recent positive developments for Azenta, including exceeding Q4 2025 revenue and EBITDA expectations, increased price targets from analysts, and a new $250 million share repurchase program.
Bear of the Day: Azenta (AZTA)
Azenta (AZTA) has been designated as the "Bear of the Day" due to a turbulent year characterized by a stock decline of over 30% and ongoing sales weakness. The company faces both short-term performance issues and longer-term structural challenges, leading to reduced investor confidence and declining EPS estimates. Analysts express caution, rating Azenta as a "Strong Sell" given its high forward P/E multiple despite underperforming the broader market.
Vale and Azenta have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Vale (VALE) as its Bull of the Day due to its strong momentum, improved operational performance, attractive valuation, and nearly 7% annual dividend yield. Conversely, Azenta (AZTA) has been designated as the Bear of the Day due to its turbulent year, struggles with sales weakness, and declining EPS revisions, leading to a "Strong Sell" rating. The article also recommends several REIT stocks, including Prologis (PLD), Simon Property Group (SPG), and Cousins Properties (CUZ), for their reliable income and growth potential heading into 2026.
Bear of the Day: Azenta (AZTA)
Azenta (AZTA) has been designated as the "Bear of the Day" due to a turbulent 2025, with its stock falling over 30% amidst ongoing sales weakness and structural challenges in its medical solutions business. Despite meeting recent EPS and sales estimates, the company's revenue contracted, and EPS estimates for fiscal 2026 and FY27 have declined significantly. With a high forward P/E multiple and a Zacks Rank #5 (Strong Sell), the stock faces continued pressure until sustained revenue growth or operational improvements are demonstrated.
Bear of the Day: Azenta (AZTA)
Azenta (AZTA) stock fell over 30% in 2025 due to ongoing sales weakness and struggles in its services for drug development, clinical research, and advanced cell therapies. The company's revenue has been soft, failing to sustain above $500 million, and its EPS estimates have declined. With a Zacks Rank #5 (Strong Sell) and a high forward P/E multiple despite underperformance, Azenta faces continued pressure until it demonstrates sustained revenue growth or operational improvements.
Azenta divests B Medical Systems to streamline portfolio
Azenta announced the sale of its B Medical Systems business for US$63 million, aiming to streamline its portfolio and focus on core capabilities. The divestiture is expected to close by March 31, 2026, with proceeds strengthening the business and supporting long-term shareholder value creation. An analyst has rated AZTA stock as a Buy with a $44.00 price target, while TipRanks' AI Analyst, Spark, rates it as Neutral due to a mix of strengths and challenges.
Azenta divests B Medical Systems to streamline portfolio
Azenta has divested its B Medical Systems business to a strategic buyer, enabling the company to better focus on its core life sciences platforms. This move is expected to streamline Azenta's portfolio and enhance shareholder value. Further details regarding the transaction were not immediately available.
Azenta (AZTA): Buy, Sell, or Hold Post Q3 Earnings?
Azenta (AZTA) shares have moved in lockstep with the market, returning 12.3% over the last six months. However, the company faces challenges with declining revenue, decreasing EPS, and a negative free cash flow margin, leading analysts to be cautious about its future performance. Despite its current valuation, the provided analysis suggests Azenta does not pass a quality test and recommends investors look for more timely opportunities.
Why Azenta is selling medical fridge maker B Medical Systems for $63M
Azenta (NASDAQ: AZTA) has signed a binding agreement to sell its B Medical Systems business to THELEMA S.À R.L. for US$63 million, with the sale expected to close by March 31, 2026. This divestiture aims to simplify Azenta's portfolio and prioritize core capabilities, with the proceeds intended to strengthen the company and create long-term shareholder value. The announcement follows several shareholder-focused moves by Azenta, including a share repurchase program and strong fiscal year results.
Azenta to sell B Medical Systems business for $63 million
Azenta, Inc. announced its affiliate, Azenta Germany GmbH, has signed an agreement to sell its B Medical Systems business to THELEMA S.À R.L. for $63 million. This transaction, representing about 4% of Azenta's market capitalization, is expected to close by March 31, 2026, and aligns with Azenta's strategy to streamline its portfolio and strengthen its core capabilities. The proceeds will be used to enhance the company and create long-term shareholder value.
Is Azenta’s Buyback and M&A Push Recalibrating the Investment Case For Azenta (AZTA)?
Azenta, Inc. announced a US$250 million share repurchase program and a strategy for disciplined M&A focused on high-margin life sciences assets. These moves, coupled with a debt-free balance sheet, aim to reshape its investment narrative by prioritizing capital allocation and margin expansion. While growth in consumables and services is crucial, the company projects revenue of $684.6 million and earnings of $34.5 million by 2028, with a fair value estimate of $39.83.
Is Azenta’s Buyback and M&A Push Recalibrating the Investment Case For Azenta (AZTA)?
Azenta (AZTA) announced a US$250 million share repurchase program and a disciplined M&A strategy targeting high-margin life sciences assets. These capital allocation decisions, alongside a debt-free balance sheet and an active M&A funnel of 60 potential targets, are set to reshape its investment narrative. While the moves don't eliminate risks from demand volatility, they aim to sharpen focus on execution and sustainable margin expansion.
Form DEFR14A Azenta, Inc.
This DEFR14A filing from Azenta, Inc. outlines the agenda for their Annual Meeting of Shareholders on January 28, 2026, including the election of directors, an advisory vote on executive compensation, and a proposal to increase shares for their 2020 Equity Incentive Plan. It details the company's executive compensation structure, corporate governance principles, and financial performance highlights for fiscal year 2025. The document also addresses a clawback analysis conducted due to financial statement revisions.
Is Azenta’s US$250 Million Buyback And M&A Push Altering The Investment Case For AZTA?
Azenta, Inc. recently announced a US$250 million share repurchase program and an active M&A pipeline targeting margin-accretive, recurring-revenue assets. This demonstrates a sharpened capital allocation strategy aimed at addressing perceived undervaluation and growing the company. While the buyback signals management confidence, the company's investment narrative still hinges on stabilizing demand in Gene Synthesis and capital equipment, alongside managing the risk of prolonged customer budget constraints.
Azenta outlines 3%–5% organic revenue growth and 300 bps margin expansion for 2026 amid operational overhaul
Azenta, a leading provider of life sciences solutions, has outlined its operational transformation plan for 2026, targeting 3%–5% organic revenue growth and a 300 basis point margin expansion. The initiatives include optimizing its global network, improving operating discipline through lean methodologies, and focusing on high-growth segments in gene and cell therapy, drug discovery, and clinical development. The company aims to achieve a mid-single-digit percentage increase in organic revenue and an adjusted operating margin in the mid-to-high teens for the full year 2026.
